345 related articles for article (PubMed ID: 25511105)
1. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A
Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study.
Dahlke M; Halabi A; Canadi J; Tsubouchi C; Machineni S; Pang Y
J Clin Pharmacol; 2016 Apr; 56(4):474-83. PubMed ID: 26239266
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations.
Dahlke M; Ng D; Yamaguchi M; Machineni S; Berger S; Canadi J; Rajman I; Lloyd P; Pang Y
J Clin Pharmacol; 2015 Apr; 55(4):415-22. PubMed ID: 25408331
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU.
Maggioni AP; López-Sendón J; Nielsen OW; Hallén J; Aalamian-Mattheis M; Wang Y; Ertl G
Eur J Heart Fail; 2019 Mar; 21(3):322-333. PubMed ID: 30604559
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of serelaxin in patients with acute or chronic heart failure, hepatic or renal impairment, or portal hypertension and in healthy subjects.
Soubret A; Pang Y; Yu J; Dahlke M
Br J Clin Pharmacol; 2018 Nov; 84(11):2572-2585. PubMed ID: 30014598
[TBL] [Abstract][Full Text] [Related]
7. Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure.
Sato N; Takahashi W; Hirayama A; Ajioka M; Takahashi N; Okishige K; Wang X; Maki A; Maruyama H; Ebinger U; Yamaguchi M; Pang Y; Matsumoto H; Kawana M
Circ J; 2015; 79(6):1237-47. PubMed ID: 25912697
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
[TBL] [Abstract][Full Text] [Related]
9. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
[TBL] [Abstract][Full Text] [Related]
10. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
[TBL] [Abstract][Full Text] [Related]
11. Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.
Ghosh RK; Banerjee K; Tummala R; Ball S; Ravakhah K; Gupta A
Cardiovasc Ther; 2017 Feb; 35(1):55-63. PubMed ID: 27727514
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment.
Kropeit D; McCormick D; Erb-Zohar K; Moiseev VS; Kobalava ZD; Stobernack HP; Zimmermann H; Rübsamen-Schaeff H
Br J Clin Pharmacol; 2017 Dec; 83(12):2678-2686. PubMed ID: 28722153
[TBL] [Abstract][Full Text] [Related]
13. Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment.
Hoover R; Marbury TC; Preston RA; Quintas M; Lawrence LE; Paulson SK; Luke DR; Cammarata SK
J Clin Pharmacol; 2017 Mar; 57(3):328-335. PubMed ID: 27570245
[TBL] [Abstract][Full Text] [Related]
14. Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients.
Reyes JF; Vargas R; Kumar D; Cullen EI; Perdomo CA; Pratt RD
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):9-17. PubMed ID: 15496218
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of nifedipine GITS/candesartan fixed-dose combination in subjects with hepatic impairment
.
Liu Y; Boettcher MF; Schmidt A; Unger S; Halabi A; Brendel E; Blode H
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):246-255. PubMed ID: 28025965
[TBL] [Abstract][Full Text] [Related]
16. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.
Peveling-Oberhag J; Zeuzem S; Yong WP; Kunz T; Paquet T; Bouillaud E; Urva S; Anak O; Sellami D; Kobalava Z
Clin Ther; 2013 Mar; 35(3):215-25. PubMed ID: 23453404
[TBL] [Abstract][Full Text] [Related]
17. Effects of Mild to Severe Hepatic Impairment on the Pharmacokinetics of Sonidegib: A Multicenter, Open-Label, Parallel-Group Study.
Horsmans Y; Zhou J; Liudmila M; Golor G; Shibolet O; Quinlan M; Emotte C; Boss H; Castro H; Sellami D; Preston RA
Clin Pharmacokinet; 2018 Mar; 57(3):345-354. PubMed ID: 28577129
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment.
Halabi A; Maatouk H; Siegler KE; Faisst N; Hinrichsen H
Clin Pharmacol Drug Dev; 2014 Jul; 3(4):290-6. PubMed ID: 27128835
[TBL] [Abstract][Full Text] [Related]
20. Effect of mild and moderate hepatic impairment on the pharmacokinetics and safety of carisbamate.
Moore K; Zannikos P; Solanki B; Greenspan A; Verhaeghe T; Brashear HR
J Clin Pharmacol; 2012 May; 52(5):738-46. PubMed ID: 21566203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]